Harvard Bioscience, Inc.
HBIO · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 0.7% | -6.1% | -11.3% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 58.4% | 50.7% | 56% | 57.1% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | $0 | -$0 | -$0 | $0 |
| % Margin | 1% | -4% | -228.1% | 0% |
| Other Income/Exp. Net | -$0 | -$0 | -$0 | $0 |
| Pre-Tax Income | -$0 | -$0 | -$0 | $0 |
| Tax Expense | $0 | $0 | -$0 | $0 |
| Net Income | -$0 | -$0 | -$0 | $0 |
| % Margin | -6% | -11.2% | -231.2% | 0.1% |
| EPS | -0.03 | -0.052 | -1.14 | 0 |
| % Growth | 41.7% | 95.5% | -285,100% | – |
| EPS Diluted | -0.03 | -0.052 | -1.14 | 0 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | $0 | $0 | -$0 | $0 |
| % Margin | 5.6% | 0.8% | -222% | 13% |